Sarepta Delay Due To Misinterpretation, Not Policy Change, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The agency made it clear to the Duchenne muscular dystrophy community that its message has remained consistent throughout the discussions regarding eteplirsen, despite Sarepta’s comments to the contrary.